The CJC-1295 + Ipamorelin pairing combines two approaches to stimulating growth-hormone release. Research on the individual components drives interest in recovery and body composition; the blend’s ratio and DAC status are essential parts of its identity.
Research focus: Growth-hormone signaling and recovery interest.
Choose a compound to open its research, documentation and calculator.
No FDA-approved drug product for this catalog material. Compounding eligibility and approval are separate questions.
Official source ↗CJC-1295 with DAC: 5.8–8.1 days in a human study. Ipamorelin: about 2 hours in a human IV study. Confirm the blend’s CJC identity.
Half-life describes concentration falling by half. It does not set a dosing interval, a storage period or a drug-test detection window.
Kinetics source ↗No validated common diluent for this exact material was established by the sources reviewed here. Component recipes do not establish blend compatibility.
Bacteriostatic water contains a preservative; plain sterile water does not. Preservative presence does not by itself establish compatibility or a mixed medicine’s usable period.
Preparation source ↗A study of one component does not validate the blend. Enter both documented component masses in the calculator.
Check that a source concerns the same molecule, formulation, route and population. A study of cells, animals or a different product cannot confirm the contents of a vial.
Separate CJC-1295 human studies and ipamorelin pharmacology; these are not a clinical trial of the combined vial.
Other names you may encounter: CJC blend.
Learn to read a study →Each entry keeps one schedule’s amount, frequency and cycle together. Community references, individual reports, clinical trials and prescription products describe different kinds of use. A missing duration or break stays marked as not reported.
Amounts describe mass in mg or mcg. Syringe units describe volume and depend on concentration. A cycle break is different from days off within a week.
Choose an option to explore its amounts, timing and cycle.
| When | Amount & frequency |
|---|---|
| Month 1 | 200 mcg CJC no-DAC + 200 mcg ipamorelin per injection |
| Month 2 onward | 400 mcg CJC no-DAC + 400 mcg ipamorelin per injection |
Combined mass is 400 mcg per injection initially and 800 mcg in the later stage. This option uses CJC without DAC.
A 1:1 component ratio in an individual nightly-use account.
A peptide name and vial mass cannot determine a compatible diluent, powder displacement, storage temperature or discard date. Follow the exact product’s instructions and your pharmacist’s directions.
The injection guide concerns clinician-prescribed subcutaneous medicines; it does not establish that a research-labeled material can be injected.
Start with the formulation: dry powder, prepared solution, pen, tablet and topical product can have different instructions.
General health habits and consistent observations help you assess changes. They are not evidence that a peptide’s effects will be amplified.
Choose activity that fits your health and ability. Aerobic movement and muscle-strengthening work are part of general adult activity guidance.
CDC · adult activity ↗Use a regular sleep/wake schedule and note changes in sleep quality alongside symptoms or training.
CDC · sleep habits ↗What to record: Keep a record of symptoms, prescribed medicines and clinician-ordered hormone or glucose measurements. A hormone change and a recovery benefit are different outcomes.
Check dates are editorial references, not a medical review certificate. Labels and evidence can change; consult the linked current document.
Opening values and worked examples illustrate arithmetic; they are not preparation instructions or recommended amounts. Selecting a compound labels the calculation and does not supply a dose or powder-volume correction.
Enter the documented vial mass, preparation information and target amount to see how mass and volume connect.
Enter the documented CJC-1295 and Ipamorelin masses separately, then select the component your target refers to. The result shows both component amounts in the same volume. Each concentration depends on its own component mass.
Estimate · assumes 1 mL added = total volume
For CJC-1295
1,000 mcg
Theoretical · before losses
0.2 mL
After 5 full doses
Illustration only · calculated value, without rounding
CJC-12951 mg
Ipamorelin1 mg
Saved calculations stay on this device.
Concentration = mass ÷ final volume
5 mg ÷ 1 mL = 5 mg/mLVolume = target mass ÷ concentration
1 mg ÷ 5 mg/mL = 0.2 mLU-100 markings = volume × 100
0.2 mL × 100 = 20 unitsComplete portions = floor(vial mass ÷ amount per portion).
Displayed numbers are rounded for readability; the calculation uses unrounded values.
Already have the concentration? Find the matching mL and U-100 syringe reading.
Need the concentration first? Use the Reconstitution tab.
5units
0.05 mL · 0.25 mg
0.25 mg ÷ 5 mg/mL = 0.05 mLU-100 units = mL × 100Example inputs are editable. The reading is calculated without rounding to a physical graduation.
Convert mass or liquid volume. U-100 markings always refer to a 100-units-per-mL scale.
1,000mcg
For mass → syringe volume, switch to Dosage and enter a concentration.